Taconic's litigation contesting license termination by Cellectis is dismissed

lang="EN-US"/>

Paris, July 6, 2010– Cellectis (Alternext: ALCLS), the French genome engineering specialist, announced today that the Paris Tribunal de Grande Instance has dismissed the claims filed by Taconic Artemis and Taconic Farms Inc. in December 2008 against Cellectis’ termination for breach of its license to homologous recombination patents.  

The third chamber of the Tribunal de Grande Instance decided on Tuesday, June 29, that the agreement under which Cellectis had granted Taconic a sublicense to the patents (WO 90/11354) relating to certain uses of homologous recombination to perform targeted modifications in the genomic DNA of eukaryotic cells was legitimately terminated on August 6, 2008, for breach of the contractual terms by Taconic.  

Consequently since August 6, 2008, the plaintiffs, Taconic and Taconic Artemis, have had no right under said patents to create and sell transgenic animal models. Furthermore, this decision confirms that the products sold by Taconic, namely transgenic animals constructed using the teaching of the patents, could not and still cannot be bred by a third party.  

The Court recognized that Cellectis had suffered losses and damages, for which Cellectis will receive financial compensation.  

An extract of the Tribunal de Grande Instance judgment is available on Cellectis’ websitehttp://www.cellectis.com/en/news-events/. 

lang="EN-US"/>